Alteration of lymphocyte function in nzb/nzw mice

Abstract

NZB/NZW F1 female mice received levamisole in an attempt to increase suppressor T cell function. Responses varied with dosage of drug and age of mice. When treatment with 25 μg/gm doses (intermittent or daily) was begun at 12 weeks of age, nephritis was accelerated in spite of transient reduction of anti‐DNA antibodies. When treatment was begun at 4 weeks, or when doses of 250 μg/gm were given, no clinical effects were observed. In the mice with accelerated disease, delayed hypersensitivity and antibody responses to sheep erythrocytes increased; antibody responses to pneumococcal poiysaccharide were unaffected. It is possible that some increased immune responses associated with levamisole are undesirable in murine lupus.

Efefct of long‐term treatment with circulating thymic factor on murine lupus

“…AntiDNA antibody production, especially that of antiDNA antibodies of the IgG class, starts very early in life and is highly sensitive to the activity of helper T cells in female B/W mice, since neonatal thymectomy reduces it to the level of male B/W mice (33). Therefore, the increase of anti-DNA antibody under T cell stimulation is not an unexpected result and might contribute to the aggravation of the renal lesions often reported in B/W mice undergoing T cell stimulation (32,34,35).…”

The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice

“…Such agents include levamisole [6], frentizole [7], cyclosporin A [8][9][10][11], N-(2-carboxyphenyl)-4-chloroanthranilic acid (CCA) [12.13], LS 2616 [14]. Wy 40453 [15].…”